Polypharmacy and Antibody Response to SARS-CoV-2 Vaccination in Residents of Long-Term Care Facilities : The GeroCovid Vax Study
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG..
BACKGROUND AND OBJECTIVE: Polypharmacy is common in older adults, particularly among those living in long-term care facilities. This condition represents a marker of clinical complexity and might directly affect the immunological response. However, there are limited data on the association of polypharmacy with vaccine immunogenicity. This study evaluated the immune response to anti-SARS-CoV-2 vaccines in older residents of long-term care facilities as a function of the number of medications used.
METHODS: In 478 long-term care facility residents participating in the GeroCovid Vax study, we assessed SARS-CoV-2 trimeric S IgG levels through chemiluminescent assays before the vaccination and after 2, 6, and 12 months. A booster dose was administered between 6- and 12-month assessments. Sociodemographic information and data on chronic diseases and medications were derived from medical records. Based on the number of daily medications, residents were classified into the no polypharmacy (zero to four medications), polypharmacy (five to nine medications), and hyperpolypharmacy (ten or more medications) groups.
RESULTS: In the sample (mean age 82.1 years, 69.2% female), 200 (41.8%) residents were taking five or fewer medications/day (no polypharmacy), 229 (47.9%) had polypharmacy, and 49 (10.3%) had hyperpolypharmacy. Using linear mixed models adjusted for potential confounders, we found that hyperpolypharmacy was associated with a steeper antibody decline after 6 months from the first vaccine dose administration (β = - 0.29, 95% confidence interval - 0.54, - 0.03, p = 0.03) than no polypharmacy, while no significant differences were observed at 12 months.
CONCLUSIONS: The humoral immune response to SARS-CoV-2 vaccination of older residents showed only slight changes as a function of the number of medications taken. Although it seemed less durable among older residents with hyperpolypharmacy, the booster dose administration equalized such a difference.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Drugs & aging - 40(2023), 12 vom: 08. Dez., Seite 1133-1141 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Trevisan, Caterina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 28.11.2023 Date Revised 28.02.2024 published: Print-Electronic CommentIn: Drugs Aging. 2024 Feb 28;:. - PMID 38416396 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s40266-023-01075-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364302674 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364302674 | ||
| 003 | DE-627 | ||
| 005 | 20240229170405.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40266-023-01075-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1310.xml |
| 035 | |a (DE-627)NLM364302674 | ||
| 035 | |a (NLM)37938521 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Trevisan, Caterina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Polypharmacy and Antibody Response to SARS-CoV-2 Vaccination in Residents of Long-Term Care Facilities |b The GeroCovid Vax Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.11.2023 | ||
| 500 | |a Date Revised 28.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Drugs Aging. 2024 Feb 28;:. - PMID 38416396 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG. | ||
| 520 | |a BACKGROUND AND OBJECTIVE: Polypharmacy is common in older adults, particularly among those living in long-term care facilities. This condition represents a marker of clinical complexity and might directly affect the immunological response. However, there are limited data on the association of polypharmacy with vaccine immunogenicity. This study evaluated the immune response to anti-SARS-CoV-2 vaccines in older residents of long-term care facilities as a function of the number of medications used | ||
| 520 | |a METHODS: In 478 long-term care facility residents participating in the GeroCovid Vax study, we assessed SARS-CoV-2 trimeric S IgG levels through chemiluminescent assays before the vaccination and after 2, 6, and 12 months. A booster dose was administered between 6- and 12-month assessments. Sociodemographic information and data on chronic diseases and medications were derived from medical records. Based on the number of daily medications, residents were classified into the no polypharmacy (zero to four medications), polypharmacy (five to nine medications), and hyperpolypharmacy (ten or more medications) groups | ||
| 520 | |a RESULTS: In the sample (mean age 82.1 years, 69.2% female), 200 (41.8%) residents were taking five or fewer medications/day (no polypharmacy), 229 (47.9%) had polypharmacy, and 49 (10.3%) had hyperpolypharmacy. Using linear mixed models adjusted for potential confounders, we found that hyperpolypharmacy was associated with a steeper antibody decline after 6 months from the first vaccine dose administration (β = - 0.29, 95% confidence interval - 0.54, - 0.03, p = 0.03) than no polypharmacy, while no significant differences were observed at 12 months | ||
| 520 | |a CONCLUSIONS: The humoral immune response to SARS-CoV-2 vaccination of older residents showed only slight changes as a function of the number of medications taken. Although it seemed less durable among older residents with hyperpolypharmacy, the booster dose administration equalized such a difference | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Haxhiaj, Labjona |e verfasserin |4 aut | |
| 700 | 1 | |a Malara, Alba |e verfasserin |4 aut | |
| 700 | 1 | |a Abbatecola, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Fedele, Giorgio |e verfasserin |4 aut | |
| 700 | 1 | |a Palmieri, Annapina |e verfasserin |4 aut | |
| 700 | 1 | |a Leone, Pasqualina |e verfasserin |4 aut | |
| 700 | 1 | |a Schiavoni, Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Stefanelli, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Maggi, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Sergi, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Volpato, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Incalzi, Raffaele Antonelli |e verfasserin |4 aut | |
| 700 | 1 | |a Onder, Graziano |e verfasserin |4 aut | |
| 700 | 0 | |a GeroCovid Vax Working Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs & aging |d 1996 |g 40(2023), 12 vom: 08. Dez., Seite 1133-1141 |w (DE-627)NLM01308545X |x 1179-1969 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2023 |g number:12 |g day:08 |g month:12 |g pages:1133-1141 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40266-023-01075-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2023 |e 12 |b 08 |c 12 |h 1133-1141 | ||